EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome
Medicine should no longer be used for other disorders of the gut
A review by the European Medicines Agency (EMA) has concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults. However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora’) in the gut. It was first made available in Germany in the 1950s and subsequently in Austria and Hungary.
In reaching its conclusions, EMA’s Committee for Medicinal Products for Human Use(CHMP) reviewed all available evidence on the effectiveness and safety of Symbioflor 2. The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2. The review did not find any new evidence on the effectiveness of Symbioflor 2 since the product was last approved. Available evidence suggests that the risk of harm from Symbioflor 2 is low.
A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS. However, the study had weaknesses. Benefit has not yet been established in children with IBS.
Since the available data are not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature). Submission of the study report to national authorities will be a condition for maintaining Symbioflor 2’s marketing authorisation.
The company that markets Symbioflor 2 did not submit data to support its use in ‘functional gastrointestinal disorders’ and agreed to remove this use from the medicine’s authorisation.
The CHMP recommendation will now be sent to the European Commission for a legally binding decision that will be valid throughout the EU.
|EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome||(English only)||23/06/2017|
Latest News from
A framework for the free flow of non-personal data in the EU – Q&As20/09/2017 12:25:00
With the Regulation on the free flow of non-personal data, the EC proposes a new principle that abolishes data localisation requirements while ensuring access rights to competent authorities for regulatory control.
State aid: EC approves alternative to divestment commitment for Royal Bank of Scotland19/09/2017 14:10:00
The EC has approved under EU State aid rules the alternative package proposed by the UK authorities to replace the commitment for Royal Bank of Scotland (RBS) to divest Williams & Glyn. The alternative package will increase competition in the UK SME banking market.
EC welcomes stakeholders' views on the future of EU finances19/09/2017 12:49:00
As part of the process started with the publication of the Reflection Paper on the Future of EU finances, the EC is organising on 25 September 2017 a conference on the challenges ahead of the EU budget and the ways to address them.
Juncker: ‘I don't intend to force countries to join the euro if they are not willing or not able to do so'18/09/2017 15:20:00
Jean-Claude Juncker, the President of the EC,has defended his proposal to expand the eurozone. All EU Member States should have the possibility to introduce the euro, but no one would be forced to do so, Juncker said on Thursday.
EMA concludes review of human factor VIII medicines authorised in EU.18/09/2017 13:20:00
The European Medicines Agency (EMA) has concluded that there is no clear & consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology.